Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

LATESTRYL is contraindicated in men with carcinomas of the breast or with known, or suspected, carcinomas of the prostate.

About VANTAS VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.

About SUPPRELIN LA

SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the hydron implant technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated wit
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Dec. 8 Kaiser Permanente Chairman and Chief,Executive ... today,at the World Healthcare Innovation and Technology conference ... Healthcare: Groundbreaking Innovations and,their Impact on Healthcare Delivery," ... care system where data and connectivity enable patient-centered ...
... SUNNYVALE, Calif., Dec. 8 Accuray Incorporated,(Nasdaq: ... field of radiosurgery, announced today,that 150 CyberKnife(R) Robotic ... milestone was achieved when Hospital Corporation of America,(HCA), ... System in,collaboration with consultant clinician partners at The ...
... (Amex: ETC ) ("ETC" or the "Company") ... BARA-MED(R)XD Monoplace hyperbaric oxygen chambers in the St. John ... chambers are the first computer-controlled hyperbaric chambers to be ... , Hyperbaric oxygen (HBO) chambers offer ...
Cached Biology Technology:Kaiser Permanente CEO Calls for 'Connected' Health Care 2Kaiser Permanente CEO Calls for 'Connected' Health Care 3Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 2Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 3Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 4Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 2Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 3Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 4
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 2008) Black bears that live around urban areas weigh ... likely to die violent deaths, according to a study by ... Fall 2008 issue of the journal Human-Wildlife Conflicts, ... areas around Lake Tahoe, Nevada and compared them to 10 ...
... The Marine Board-ESF published its 13th Position Paper, which ... research needed to assess the effects of anthropogenic sound ... Marine Board Position Paper 13 results from the activities ... and marine mammals convened at the joint European Marine ...
... Letters, Steve Brusatte, Professor Michael Benton, and colleagues ... not proliferate immediately after they originated, but that their ... by two mass extinctions. "The sheer size ... something special about these animals that preordained them for ...
Cached Biology News:Study: urban black bears 'live fast, die young' 2Effects of anthropogenic sound on marine mammals -- a research strategy 2Mass extinctions and the evolution of dinosaurs 2
...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... marker is specifically designed for two-dimensional ... The four proteins in this marker ... diagonal pattern across a 2D gel. ... 3.8. Mol wt: ...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 21 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
Biology Products: